Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid
OwnerMamoru Kobayashi, Tetsuya Asariinventors
Life of this patent
Estimating the term…
Loading patent…
OwnerMamoru Kobayashi, Tetsuya Asariinventors
Estimating the term…
The present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear. That is, the present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear such as dry eye, dry disorders of cornea and conjunctiva, disorders of the keratoconjunctival epithelium, syndrome with decrease in tear secretion, xerophthalmia, dry eye due to aging, opthalmopathy in Stevens-Johnson syndrome, opthalmopathy in Sjögren's syndrome, keratoconjunctival ulcer, dryness in wearing of contact lens or the like, which comprises a β3 adrenoceptor stimulant. The present invention also provides a combination pharmaceutical comprising a β3 adrenoceptor stimulant and a β2 adrenoceptor stimulant.
A method for the prevention or treatment of a disease associated with decrease in tear, which comprises administering to a patient having a disease associated with a decrease in tear a β3-adrenoceptor stimulant.
A method for the facilitation of tear secretion, which comprises administering to a patient a β3-adrenoceptor stimulant.
A method for the facilitation of protein secretion in tear, which comprises administering to a patient a β3-adrenoceptor stimulant.
Dependencies are inferred from the claim text.